Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)

Core Insights - Mainz Biomed N.V. is participating in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) from November 14-15, 2025, in Bad Kreuznach, Germany, focusing on early cancer detection [1][2] Company Overview - Mainz Biomed specializes in molecular genetics diagnostics, particularly for early cancer detection, with its flagship product being ColoAlert®, a non-invasive test for colorectal cancer [5] - The company is currently conducting the eAArly DETECT 2 clinical study in preparation for a pivotal FDA study aimed at obtaining regulatory approval in the US [5] Industry Engagement - The GARPS conference serves as a platform for knowledge exchange among clinical and scientific experts in gastroenterology and hepatology, fostering dialogue between universities, hospitals, and the diagnostics industry [2] - Mainz Biomed aims to strengthen relationships with key opinion leaders in gastroenterology and discuss future cancer prevention strategies during the conference [3] Product Promotion - Attendees at the GARPS conference are invited to learn about the importance of early colorectal cancer detection and explore potential collaborations to offer ColoAlert® to patients [4]